suPAR and Chronic Kidney Disease-A Podocyte Story

Pflugers Arch. 2017 Aug;469(7-8):1017-1020. doi: 10.1007/s00424-017-2026-7. Epub 2017 Jul 8.

Abstract

The soluble urokinase-type plasminogen activator receptor (suPAR) is a circulating signaling molecule derived from immature myeloid cells. Elevated levels of suPAR have been linked to the pathogenesis of the kidney disease focal and segmental glomerulosclerosis. Here, suPAR acts on podocytes by activating αvβ3 integrins. Large observational studies showed that suPAR also predicts chronic kidney disease incidence and progression by predating the disease by several years prior to any other known marker of renal dysfunction. suPAR is rapidly developing into a prime target for pharmacotherapy as its neutralization is forecasted to be feasible and safe.

Keywords: CKD; FSGS; Integrin; Podocyte; suPAR.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / blood
  • Glomerulosclerosis, Focal Segmental / blood
  • Glomerulosclerosis, Focal Segmental / drug therapy
  • Glomerulosclerosis, Focal Segmental / metabolism*
  • Glomerulosclerosis, Focal Segmental / pathology
  • Humans
  • Integrin alphaVbeta3 / metabolism
  • Podocytes / metabolism*
  • Receptors, Urokinase Plasminogen Activator / blood
  • Receptors, Urokinase Plasminogen Activator / metabolism*
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / drug therapy
  • Renal Insufficiency, Chronic / metabolism*
  • Renal Insufficiency, Chronic / pathology

Substances

  • Biomarkers
  • Integrin alphaVbeta3
  • Receptors, Urokinase Plasminogen Activator